New indications and platforms for CAR-T therapy in lymphomas beyond DLBCL

[摘要] CD19-directed chimeric antigen receptor T-cell therapy (CAR-T) represents a significant advancement for patients with relapsed/refractory large B-cell lymphoma (LBCL). Long-term follow-up confirms durable remissions in nearly half of the patients, a population that was previously estimated to have a median survival of around 6 months with standard salvage therapy. This initial success of CAR-T has led to significant expansion across other lymphoma histologies resulting in the recent regulatory approval of CAR-T in mantle cell lymphoma and follicular lymphoma. Additionally, multiple novel platforms of CAR-T therapy are under development to improve efficacy and limit toxicity such dual antigen targeting, allogeneic and natural killer CARs. In this review, we focus on the new indications of CAR-T in lymphomas beyond LBCL as well as emerging platforms of CAR-T therapy.

[关键词] allogeneic CAR;CAR-T;dual CAR;follicular lymphoma;lymphoma;mantle cell